Comparison

Cagrilintide vs. Liraglutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Liraglutide
Germany	Unapproved	Prescription
DK	Unapproved	—
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Liraglutide?: Cagrilintide is classified as "Metabolic", while Liraglutide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Liraglutide?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Liraglutide in Germany and the United States?: Germany: Cagrilintide — Unapproved, Liraglutide — Prescription. United States: Cagrilintide — Unapproved, Liraglutide — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Liraglutide

Germany

Unapproved

Prescription

Unapproved

—

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Cagrilintide and Liraglutide?

Cagrilintide is classified as "Metabolic", while Liraglutide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Liraglutide?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Liraglutide in Germany and the United States?

Germany: Cagrilintide — Unapproved, Liraglutide — Prescription. United States: Cagrilintide — Unapproved, Liraglutide — Prescription. These are factual summaries with source and review date on the individual pages.